NewsBenzinga强生公布其 III 期 ICONIC-LEAD 研究两年新结果，该研究评估 ICOTYDE 在中重度斑块型银屑病成人患者中的疗效；数据显示至第 112 周持续保持较高水平的皮肤清除率及患者报告的症状改善，且未发现新的安全性信号 强生公布其 III 期 ICONIC-LEAD 研究两年新结果，该研究评估 ICOTYDE 在中重度斑块型银屑病成人患者中的疗效；数据显示至第 112 周持续保持较高水平的皮肤清除率及患者报告的症状改善，且未发现新的安全性信号 Benzinga 2026.10.09 11:09 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Overweight on Essential Properties, Lowers Price Target to $30 Morgan Stanley Maintains Equal-Weight on Sportradar Gr, Lowers Price Target to $13.5 Morgan Stanley Maintains Underweight on Simmons First Ntl, Raises Price Target to $27 Wells Fargo Maintains Equal-Weight on EPR Properties, Lowers Price Target to $56 Analyst Sees Billions in Walmart's Next Big Advertising Opportunity Morgan Stanley Maintains Equal-Weight on Red Rock Resorts, Lowers Price Target to $59
